Pituitary pars intermedia dysfunction (PPID) and equine metabolic syndrome (EMS) are two common equine endocrine disorders. Whilst the only drug that is currently licensed for the treatment of PPID in horses in the UK is pergolide, there are many questions that first opinion practitioners have relating to the management of this disease. The British Equine Veterinary Association (BEVA) primary care guidelines for the diagnosis and management of PPID were recently developed and will be discussed alongside the recently updated guidelines that are produced by the Equine Endocrinology Group (EEG) for this condition. Whilst diet and exercise designed to improve insulin sensitivity in animals with EMS are the main way that this condition is managed, there is increasing use of pharmacologic agents which aim to improve insulin sensitivity and consequently decrease the associated laminitis risk. The EEG guidelines for the diagnosis and management of EMS will be updated in 2024 and these will be discussed alongside the published evidence relating to the effectiveness of sodium glucose like transporter 2 (SGLT2) inhibitors.